Background {#sec1_1}
==========

Oligodendroglial tumors have generated a large amount of interest over the past years due to their heightened response to chemotherapy and ability to be divided into prognostic subgroups based on molecular biology \[[@B1]\]. Several clinical studies demonstrated that losses of portions of chromosomes 1p and 19q are associated with the oligodendroglial phenotype and longer recurrence-free survival following radiation and/or chemotherapy \[[@B2], [@B3]\]. It is believed that these chromosome regions contain tumor suppressor genes that block the development and/or progression of the tumor. Radiation therapy inducing secondary oligodendroglial tumors are very rare \[[@B4]\], the approximate cumulative risk for secondary brain tumors after cranial irradiation is 1-3% \[[@B5]\]. Only a small portion of these rare tumors correspond to oligodendroglial histology; there have been less than 10 cases reported to date \[[@B4]\].

Case Report {#sec1_2}
===========

A 32-year-old man was admitted to the Hospital Sírio-Libanês in June 2008 with a short history of progressive headache and left hemiplegia. The patient had a previous history of a lymphoblastic lymphoma with central nervous system involvement, and had been previously submitted to a variety of systemic chemotherapy regimens, including an autologous bone marrow transplantation in June 2002. Six months after that procedure the patient developed a CNS recurrence and was treated with radiation therapy which encompassed the whole brain and the neuraxis (24 Gy administered in 12 fractions), achieving a complete remission. The patient remained well and asymptomatic, without any clinical or radiological evidences of lymphoma up until shortly prior to this hospital admission, when a brain MRI was performed, showing a gross mass in the right temporal lobe ([fig. 1a, b](#F1){ref-type="fig"}). A partial tumor resection was carried out and the pathologic evaluation, based on histology and immunohistochemistry, ruled out the possibility of recurrence of the lymphoma and revealed the presence of an anaplastic oligodendroglioma. The pathologic specimen was reviewed by 3 different pathologists, who concurred with this diagnosis. A FISH assay was performed and showed the presence of 1p deletion, but not 19q deletion. During the postoperative period the patient developed a rapid neurologic deterioration (PS:4, complete left hemiplegia, severe headaches). As shown in the MRI performed after the surgical procedure, the tumor had rapidly increased in size (fig. [1c, d](#F1){ref-type="fig"}). Given the dramatic clinical course and tumor development, we decided to treat the patient with temozolomide at a dose of 150 mg/m^2^/day for 5 consecutive days every 28 days associated with bevacizumab at a dose of 10 mg/kg given on days 1 and 15. Shortly after the treatment was started, the patient\'s neurological condition markedly improved. Six weeks after starting this therapy the patient was walking with the help of a cane and the MRI showed a complete resolution of the mass effect and a complete disappearance of the contrast-enhancing tumor (fig. [1e, f](#F1){ref-type="fig"}).

Discussion {#sec1_3}
==========

The classic treatment for patients with a newly-diagnosed anaplastic oligodendroglial tumor is based on maximal surgical resection consistent with preservation of neurologic function \[[@B6]\]. Radiotherapy should be used in patients with large residual mass or with anaplastic lesions \[[@B7]\]. For selected cases with deletions in 1p and 19q, chemotherapy should also be considered, either in conjunction with radiotherapy or as a single modality \[[@B7], [@B8]\]. In our patient the usual approach could not be applied. An adequate tumor resection was not possible because of the size and location of the tumor, which also involved the contralateral hemisphere. In addition, radiation therapy was also not an option due to whole brain irradiation previously administered.

Temozolomide is a broadly utilized oral methylating agent. The activity of this drug in the treatment of high grade gliomas is well recognized. In phase II trials, temozolomide as single agent produces response rates of 50-60% in patients with anaplastic oligodendroglioma \[[@B9], [@B10]\]. There are no randomized trials evaluating the role of temozolomide in oligodendroglial tumors.

Bevacizumab is a monoclonal antibody with important anti-angiogenic properties, which inhibits the serum vascular endothelial growth factor (VEGF), a cystine-knot growth factor involved in vasculogenesis. In phase II trials, bevacizumab showed important activity and safety in patients with high-grade glioma \[[@B11], [@B12]\]. Recent data suggest that the combination of temozolomide and Bevacizumab is active in high-grade gliomas with an acceptable safety profile even when given with concomitant radiotherapy \[[@B13], [@B14]\].

The quick and significant tumor reduction seen in this patient constitutes, to our knowledge, the first report of the use of this form of therapy in an anaplastic oligodendroglioma patient. Given the previous medical history of this patient and the rapid pace of tumor growth, we were afraid that unless the initial treatment could induce important and fast tumor regression, a life-threatening condition would be reached within a matter of days.

![Seriated MRI analysis showing tumor progression and reduction over time. **a**, **b** Exam performed on 17/07/08 showing a large mass compromising temporal, parietal and occipital lobes on the T1 contrasted sequence (**a**) and on the flair sequence (**b**). **c**, **d** Exam performed on 04/08/08 showing a marked increase in tumor size in a short interval, on the contrasted T1 sequence (**c**) and on the flair sequence (**d**). **e**, **f** Exam performed on 15/09/08, 2 weeks after the second dose of temozolomide was administered, showing a complete disappearance of the contrast-enhancing mass and resolution of the mass effect on the contrasted T1 sequence (**e**) and on the flair sequence (**f**).](cro0002-0057-f01){#F1}
